Prescribing Patterns of Amantadine During Pediatric Inpatient Rehabilitation After Traumatic Brain Injury: A Multicentered Retrospective Review From the Pediatric Brain Injury Consortium.
Prescribing Patterns of Amantadine During Pediatric Inpatient Rehabilitation After Traumatic Brain Injury: A Multicentered Retrospective Review From the Pediatric Brain Injury Consortium.
复制标题
DOI：
10.1097/htr.0000000000000709
复制
发表时间：
2022-07-01
期刊：
影响因子：
--
通讯作者：
Suskauer SJ
中科院分区：
文献类型：
--
作者：
McLaughlin MJ;Caliendo E;Lowder R;Watson WD;Kurowski B;Baum KT;Blackwell LS;Koterba CH;Hoskinson KR;Tlustos SJ;Zimmerman KO;Shah SA;Suskauer SJ
目的：描述盐酸金刚烷胺给药的做法和相关的不良反应，在儿童和青少年创伤性脑损伤（TBI）承认儿科住院康复units.Setting：八个儿科急性住院康复单位位于美国各地，包括儿科脑损伤Consortium.Participants：234名儿童和青少年年龄2个月至21岁的TBI设计：回顾性数据revie.Main结果测量：人口统计学变量与金刚烷胺的使用，金刚烷胺剂量，并报告不良反应。结果：四十九名患者（21%）年龄0.9至20岁在住院康复期间接受金刚烷胺。45%的意识障碍（DoC）住院康复患者接受了金刚烷胺治疗，而14%的功能水平较高的儿童接受了金刚烷胺治疗。未接受金刚烷胺治疗的DoC儿童比接受金刚烷胺治疗的DoC儿童年轻（中位数3.0 vs 11.6岁，P= 0.001）。008）。金刚烷胺的记录剂量范围为0.7 - 13.5 mg/kg/d;最高总日剂量为400 mg/d。8例患者（16%）报告了不良反应;恶心/腹部不适和躁动是最常见的，各有3例患者报告。无不良反应的最高报告剂量为10.1 mg/kg/d。结论：在儿科住院康复期间，金刚烷胺被处方给不同年龄和损伤严重程度的儿童，最常见的处方是年龄较大的DoC儿童。剂量变化很大，对于年龄较小/较小的儿童，基于体重的剂量比先前报告的剂量低和高。需要进行前瞻性研究，以确定更高剂量金刚烷胺的安全性和耐受性，并优化金刚烷胺给药参数。
Objectives:To describe dosing practices for amantadine hydrochloride and related adverse effects among children and young adults with traumatic brain injury (TBI) admitted to pediatric inpatient rehabilitation units.Setting:Eight pediatric acute inpatient rehabilitation units located throughout the United States comprising the Pediatric Brain Injury Consortium.Participants:Two-hundred thirty-four children and young adults aged 2 months to 21 years with TBI.Design:Retrospective data revie.Main Outcome Measures:Demographic variables associated with the use of amantadine, amantadine dose, and reported adverse effects.Results:Forty-nine patients (21%) aged 0.9 to 20 years received amantadine during inpatient rehabilitation. Forty-five percent of patients admitted to inpatient rehabilitation with a disorder of consciousness (DoC) were treated with amantadine, while 14% of children admitted with higher levels of functioning received amantadine. Children with DoC who were not treated with amantadine were younger than those with DoC who received amantadine (median 3.0 vs 11.6 years, P=. 008). Recorded doses of amantadine ranged from 0.7 to 13.5 mg/kg/d; the highest total daily dose was 400 mg/d. Adverse effects were reported in 8 patients (16%); nausea/abdominal discomfort and agitation were most common, each reported in 3 patients. The highest reported dose without an adverse effect was 10.1 mg/kg/d.Conclusion:During pediatric inpatient rehabilitation, amantadine was prescribed to children across a range of ages and injury severity and was most commonly prescribed to older children with DoC. Dosing varied widely, with weight-based dosing for younger/smaller children at both lower and higher doses than what had been previously reported. Prospective studies are needed to characterize the safety and tolerability of higher amantadine doses and optimize amantadine dosing parameters for children with TBI.